Contents

Search

carbidopa/entacapone/levodopa (Stalevo)

Tradename: Stalevo Contains carbidopa/levodopa & entacapone. Indications: -> Parkinson's disease a) for those patients already taking Sinemet plus entacapone b) for those patients wearing off Sinemet Dosage: -> one tablet/dose; maximum 8 tablets/day Tabs: 3 strengths of carbidopa/levodopa - 12.5/50, 25/100 37.5/150 (mg/mg) - 200 mg of entacapone Adverse effects: 1) see Sinemet & entacapone 2) most common a) dyskinesia b) orthostatic hypotension c) hallucinations 3) prostate cancer ? [3] 4) increased cardiovascular risk relative to Sinemet [4] - no risk in risk of cardiovascular events [5]

General

combination therapy for Parkinson's disease

References

  1. Prescriber's Letter 10(8):45 2003
  2. Bronstein J, In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 29-Oct 2, 2004
  3. FDA Medwatch Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm206934.htm
  4. FDA Medwatch Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm223423.htm
    1. FDA Safety Alert. Oct 26, 2015 Entacapone: Drug Safety Communication - FDA Review Found No Increased Cardiovascular Risks. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm469162.htm

Components

carbidopa (Lodosyn) entacapone (Comtan) levodopa; L-3-hydroxytyrosine; L-3,4-dihydroxyphenylalanine; L-dopa (Dopar, Larodopa, Inbrija)